AptarGroup, Inc.

NYSE:ATR

Medical - Instruments & Supplies

Healthcare
$141.67 +0.55%

+$0.66 today

Market cap
$8.98B
Beta
0.40
P/E (TTM)
20.0
EPS (TTM)
$6.04
Dividend yield
1.57%
52W Low $103.23High $164.28

Volume 0.34M

Average 0.51M

ATR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

AptarGroup, Inc.NYSE: ATR

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA dips below year-ago levels

Q2 FY2026 EBITDA of $207.78M fell 5.8% year over year, behind the +1.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 11.4% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.

Context

  • EBITDA amounted to 22.0% of revenue in FY2025, up 0.3 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of $827.97M (-0.4%) for the fiscal year ending Dec 2026, a slowdown from the +6.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$207.78M+11.4% QoQ
Last fiscal yearDec 2025
$831.48M+6.9% YoY
LTMJun 2026
$822.22M+1.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.8%-11.7%-5.9 pp
1 year+6.9%-0.4%-7.4 pp
3-year CAGR+10.9%+3.4%-7.5 pp
5-year CAGR+7.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
831.48M USD
Year-over-year change
+6.9%
4-year CAGR
+9.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ATR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.7% is the 5th highest of 7, against a peer median of +11.3%.
  • EBITDA amounts to 20.9% of revenue for ATR, versus a peer median of 15.4%.
ATR Competitors
EBITDA for ATR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMCRAmcor plcLTM Jun 2026$3.47B USD+96.5%+16.6%14.8%
SLGNSilgan Holdings Inc.LTM Jun 2026$928.91M USD+8.2%+2.0%13.9%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$870.4M USD+14.5%-1.6%26.2%
ATRAptarGroup, Inc.LTM Jun 2026$822.22M USD+1.7%+10.9%20.9%
SONSonoco Products CompanyLTM Sep 2026$724.61M USD-11.3%+20.7%9.8%
STVNStevanato Group S.p.A.LTM Jun 2026€296.36M EUR-4.5%+4.4%24.3%
TRSTriMas CorporationLTM Mar 2026$138.51M USD+42.0%-13.8%16.0%
Peer median (excluding ATR) —+11.3%+3.2%15.4%

Competitors are the stored peer set for ATR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.23B3.32B3.49B3.58B3.78B
Cost of Revenue2.07B2.16B2.22B2.23B2.66B
Gross Profit1.16B1.16B1.26B1.36B1.12B
Gross Margin35.8%35.0%36.2%37.8%29.6%
Research & Development99.8M000105.1M
Selling, General & Admin551.24M544.26M565.78M582.23M499.94M
Operating Expenses809.34M784.57M859.38M859.01M605.04M
Depreciation & Amortization234.85M233.71M248.59M263.78M287.36M
EBITDA586.79M609.41M663.84M777.45M831.48M
EBITDA Margin18.2%18.3%19.0%21.7%22.0%
Operating Income347.35M379.27M404.02M496.5M512.34M
Operating Margin10.8%11.4%11.6%13.9%13.6%
Interest Income3.67M2.7M4.37M12.1M11.68M
Interest Expense30.28M40.83M40.42M43.9M52.74M
Other Income / Expenses(25.69M)(44.57M)(29.19M)(26.73M)(20.96M)
Income Before Tax321.66M334.7M374.83M469.77M491.38M
Pre-Tax Margin10.0%10.1%10.7%13.1%13.0%
Income Tax Expense78.02M95.15M90.65M95.59M98.88M
Net Income244.1M239.29M284.49M374.54M392.79M
Net Margin7.6%7.2%8.2%10.5%10.4%
EPS (Basic)3.723.664.345.655.97
EPS (Diluted)3.603.594.255.535.88
Weighted Avg Shares65.66M65.4M65.62M66.33M65.74M
Weighted Avg Shares (Diluted)67.68M66.72M66.91M67.69M66.72M

AptarGroup, Inc.

NYSE:ATR

Intrinsic Alpha fair value

Locked

Current Price

$141.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.